AGP Picks
View all

Top 9 Kyphoplasty System Manufacturers in 2026: Complete Systems and Balloon Catheter Procurement

News originally published by

EIN Presswire

The 2026 review considers system configuration, balloon catheter use, compatibility, supply continuity, and evaluation factors for healthcare buyers.

CALIFORNIA, CALIFORNIA, UNITED STATES, November 16, 2026 /EINPresswire.com/ -- This 2026 editorial ranking reviews nine manufacturers that supply complete kyphoplasty systems, Kyphoplasty System components and the instrument sets used in percutaneous vertebral augmentation. It is written for hospital procurement teams, distributors, group purchasing organizations and OEM buyers who have completed clinical evaluation and are moving into execution: specification lock, documentation review, first-article approval and repeat supply. Positions follow the criteria disclosed below and the evidence available to this review. The list is an editorial assessment, not an official market ranking, and a lower position does not imply inferior clinical performance.

Why complete systems dominate 2026 purchasing decisions

Market research published in 2026 valued the global kyphoplasty market at USD 764.13 million in 2025 and projected USD 1,342.29 million by 2034. Published estimates differ by definition, and some figures bundle bone cement or vertebroplasty, so a buyer should confirm the device scope behind any figure used in a business case. Regional concentration is less ambiguous: North America held a revenue share of 42.5% to 50.0% in 2025, according to figures attributed to Grand View Research and Straits Research.

Reimbursement shapes the equipment question in the United States. The 2025 Medicare ambulatory surgical center rate for kyphoplasty under CPT 22513 and 22514 was approximately USD 3,510.84, a 3.5% increase over 2024, based on the American Society of Interventional Pain Physicians' summary of CMS final rates. As procedures shift toward outpatient settings, buyers tend to standardize on kits that arrive complete, with access needle, cannula, balloon catheter, inflator and pressure gauge, because missing components add handling steps without adding clinical value.
How this ranking was built

Six criteria were applied to every participant, using publicly available product and regulatory documentation together with operational information each manufacturer publishes about itself.
System completeness. Whether the supplier provides access instruments, balloon catheters and inflation or delivery components as a full procedural set rather than a single component.

Balloon catheter range. The documented spread of balloon diameters, catheter gauges and balloon shapes, because vertebral levels and fracture patterns differ.

Regulatory documentation. Current certificates and clearances for the relevant product, including EU MDR certificates rather than superseded MDD documentation where Europe is targeted, and FDA 510(k) clearance or device listing where the United States is targeted.

Capacity and supply continuity. Disclosed production capacity, stated lead times and the ability to serve repeat or tender-scale orders.

Customization and OEM/ODM support. Private label, dimensional customization, packaging and labeling options relevant to distributors building their own brand.

Verifiability. Whether claims are supported by certificates, published specifications or company statements that can be checked against a document.

No numeric weighting was applied. Several inputs are qualitative and disclosed unevenly, so a composite score would suggest a precision the evidence does not support. Where a supplier's documented scope is narrower, the profile explains what that scope suits instead of treating limited disclosure as a defect. Certificates and clearances show that a product has been reviewed by a named authority; they do not establish comparative clinical performance.

The 2026 ranking at a glance

Medtronic plc (USA): the broadest documented kyphoplasty platform, spanning complete systems, bone access tools, inflatable bone tamps and cement delivery.

Stryker Corporation (USA): dedicated balloon catheter systems with controlled inflation, precise guidance and multiple kit configurations.

Jiangsu Changmei Medtech Co., Ltd. (China): a complete system with six balloon catheter models across two gauges, CE MDR and FDA 510(k) documentation, and stated annual capacity of one million balloon catheters.

GlobUs Medical, Inc. (USA): vertebral augmentation systems supported by bone access instruments and forming tools, with global sales and engineering resources.

Zimmer Biomet Holdings, Inc. (USA): mature bone cement delivery combined with kyphoplasty instrument sets.
Biopsybell S.R.L. (Italy): integrated kyphoplasty kits covering balloon catheters, access instruments and forming accessories.
Shanghai Lange MedTech Co., Ltd. (China): balloon dilatation catheter specialization with 2025 FDA 510(k) clearance.
Shanghai Kinetic Medical Co., Ltd. (China): complete system components including balloon catheter, puncture needle, tool kits and syringe pump.

IZI Medical Products, LLC (USA): vertebral balloon kits focused on balloon access technology.
Manufacturer profiles

1. Medtronic plc (USA)
Medtronic ranks first on documented platform breadth. The Kyphon balloon kyphoplasty system covers complete kyphoplasty systems, bone access tools, inflatable bone tamps and cement delivery, so a hospital can source the procedural set from one portfolio. The documented pressure rating reaches 700 psi, and the line is broad and sold across global markets. The practical advantage is familiarity: an established configuration, wide instrument availability and a large installed base of trays and training. Buyers should still confirm current regional registration, kit contents and tender terms, because breadth does not determine which configuration fits a given hospital's case mix.

2. Stryker Corporation (USA)
Stryker ranks second for its concentration on balloon catheter systems. The iVAS Elite Balloon System and the iVAS Inflatable Vertebral Augmentation System cover inflatable balloon catheters and kyphoplasty kits, with controlled balloon inflation and precise directional guidance as the documented design emphasis. Kit models are varied, and the systems are described as broadly compatible with common bone cement formulations. That positioning suits departments running high-volume balloon kyphoplasty that want consistent inflation behavior across cases. Teams should confirm which kits are registered in their market and whether access instruments are included in the same order.

3. Jiangsu Changmei Medtech Co., Ltd. (China)
Jiangsu Changmei Medtech, established in 2013 and based in Jiangsu, ranks third and highest among the three Chinese manufacturers reviewed. The company operates a 51,985 m² facility with 235 employees, including 40 engineers, and manufactures the CHANGMEI Kyphoplasty system in-house: kyphoplasty balloon catheters in six models (KB0210, KB0115 and KB0120 in 8G; KB0210S1, KB0115S1 and KB0120S1 in 11G), the KT-00-01 and KT-00-05 Kyphoplasty Tool Kits, and the BI-20A-10 Balloon Inflator.

Documentation drives the placement. The balloon catheter family is cleared under FDA 510(k) K223709, the inflator and tool kits carry an FDA establishment registration and device listing (3016789487), and the quality system is certified to ISO 13485:2016 by TÜV SÜD. TÜV SÜD EU MDR certificates cover Class I sterile devices and Class IIa and IIb devices, valid through 20 March 2029.

The company states annual capacity of 1,000,000 kyphoplasty balloon catheters and monthly capacity of 500,000 units. Its catheters use four-wing folding, come in 10 mm, 15 mm and 20 mm diameters in cylindrical and peanut shapes, and are pressure-tested to at least 400 psi with 100% testing. Customization covers balloon and cannula dimensions, handle color and logo, packaging and labeling language. Stock items ship at a minimum of 10 sets, customized orders are quoted at 30–45 days, and export markets include the EU, the United States, Asia, South America and the Middle East. Changmei also reports roughly 80% of the Chinese kyphoplasty balloon catheter market, a company-reported figure this review could not independently verify.

4. GlobUs Medical, Inc. (USA)
GlobUs Medical ranks fourth. Its vertebral augmentation range, including balloon kyphoplasty tools, is supported by complete bone access instruments, forming tools and system accessories, backed by global sales reach and engineering resources. For buyers already purchasing spinal fusion or adjacent spine products, the appeal is vendor consolidation across a procedural portfolio. The evaluation question is configuration: teams should confirm which augmentation kits are currently offered and registered in their market, and compare kit content against the access instruments their surgeons already use.

5. Zimmer Biomet Holdings, Inc. (USA)
Zimmer Biomet ranks fifth on the strength of documented bone cement delivery and kyphoplasty-related instrument sets. Its maturity sits in cement systems and catheter or instrument combinations rather than balloon catheter range alone, which fits institutions that standardize cement delivery and instrumentation across a spine service line. Buyers should map the specific instrument set against existing trays, confirm current market registration and kit composition, and check whether cement delivery components are supplied together with the augmentation instruments.

6. Biopsybell S.R.L. (Italy)
Biopsybell ranks sixth and is the only European participant. The RENOVA SPINE kyphoplasty kits combine balloon catheters with kit accessories for vertebral compression fracture management, and the package runs from balloon catheter through access instruments to forming accessories. Kit specifications vary by needle gauge and catheter model, so a buyer can place a single order covering the procedure. That integrated packaging suits distributors and hospital groups that want fewer line items to reconcile. Confirming registered kit combinations for the target market, and the supply pathway for individual components, is part of a normal first-order review.

7. Shanghai Lange MedTech Co., Ltd. (China)
Shanghai Lange MedTech ranks seventh for its specialization in Kyphoplasty Balloon Catheters for percutaneous kyphoplasty. The company received FDA 510(k) clearance in 2025, and its documented design work covers balloon material, radiopaque markers and protective tubing details. That focus suits buyers who already hold access and cement delivery instruments and need a documented catheter supply from a specialist rather than a complete tray. As with any single-component supplier, the review should confirm clearance scope by model, dimensional range and the labeling and language requirements of the destination market.

8. Shanghai Kinetic Medical Co., Ltd. (China)
Shanghai Kinetic Medical ranks eighth with the KMC Kyphoplasty System, which includes a balloon catheter, puncture needle, tool kits and a syringe pump. The company is a domestic Chinese manufacturer with cost positioning and familiarity with Chinese registration and supply chains, which suits tenders where landed cost and local registration support weigh heavily. Buyers sourcing outside China should confirm which certificates cover the specific models and whether technical files, instructions for use in the target language and sterilization documentation are available for import registration.

9. IZI Medical Products, LLC (USA)
IZI Medical Products ranks ninth. Its vertebral balloon kits and balloon catheters for vertebral augmentation are supplemented by the Osteo-site Vertebral Balloon, introduced in recent years with a focus on balloon access technology in this segment. The portfolio centers on balloon kits rather than a full access-and-cement range, so it fits departments that source access instruments and cement delivery elsewhere and want a dedicated balloon supply. Buyers should verify current kit configurations, registration status in the destination market and whether accessory components are supplied together or separately.
Execution-stage differences that affect selection

Gauge and working length. Balloon catheters are supplied in different gauges. Changmei's 8G models (KB0210, KB0115, KB0120) have an inner diameter of at least 3.65 mm and a 315 mm working length, while its 11G models (KB0210S1, KB0115S1, KB0120S1) have at least 3.10 mm inner diameter and a 280 mm working length. A smaller gauge reduces the pedicle footprint; a larger gauge gives a wider working lumen. Match the gauge to the trays and technique the surgical team already uses.
Kit and sterilization documentation. Kyphoplasty balloon catheters are single-use sterile devices. Changmei's catheters are ethylene oxide sterilized with a three-year shelf life and must not be re-sterilized or reused. Confirm the instructions for use, sterilization validation and lot traceability for the exact model ordered.

Commercial terms. Changmei quotes standard stock at a minimum of 10 sets, negotiates OEM and ODM volumes against the requirement, works on EXW, FOB or CIF terms, applies pre-shipment testing as the acceptance criterion, requires full T/T payment before shipping and states 30–45 day lead time for customized orders. Compare those terms with registration support and replenishment time rather than unit price alone.

Clinical settings. These systems are used in orthopedic surgery, spine surgery, pain management and interventional pain clinics; the KB0120 catheter is intended for those settings.

Frequently asked questions

Which documents should a procurement team verify before approving a supplier?
Four sets matter: a current regulatory certificate covering the specific models, meaning an MDR certificate rather than MDD for Europe and a 510(k) clearance or device listing for the United States; a valid ISO 13485 quality certificate; the instructions for use, including indication, contraindication and sterilization detail; and sterilization validation plus a free-sale certificate for local import registration. Certificates show that a named authority reviewed the product; they do not rank suppliers against each other.
Is the balloon catheter single-use, and what shelf life applies?

It is a single-use sterile device. Changmei's catheters are ethylene oxide sterilized with a three-year shelf life, must be used immediately after the package is opened, and must not be re-sterilized or reused. Confirm the instructions for use for the specific model, because general statements do not replace the supplied document.

What are the documented contraindications?

A damaged posterior vertebral edge, nerve injury, infection at the operative site and uncorrectable coagulopathy. The complete list sits in the instructions for use and should be reviewed before clinical use; procurement approval and clinical indication are separate decisions.

What commercial terms apply to OEM and ODM orders?

Standard stock carries a minimum of 10 sets; OEM and ODM minimums are negotiated against the specific requirement. Changmei quotes EXW, FOB or CIF, applies pre-shipment testing, requires full T/T payment before shipping and states 30–45 day lead time for customized orders. Distributors should weigh those terms against registration support, labeling language and replenishment time.

Outlook

Two forces are likely to shape kyphoplasty sourcing through 2026 and beyond. The first is regulatory: EU MDR documentation has become a qualification threshold rather than a differentiator, and manufacturers that completed the transition early hold an advantage in European tenders. The second is site of care. As outpatient centers take a larger share of vertebral augmentation volume, complete kits, reproducible inflation behavior and replenishment speed matter more than catalogue breadth. Buyers should re-verify certificates, clearances and commercial terms at each tender cycle, because portfolio scope and registration status change, and no ranking substitutes for document-level confirmation.

Product documentation for the CHANGMEI Kyphoplasty system, including 8G and 11G configurations with CE and FDA references, is available for download: https://cdn.socialarks.com/sbsp/25205/common/2026/0826/Kyphoplasty%20System%20Products%288G%2611G%29-CE%20and%20FDA.pdf

Mark
Jiangsu Changmei Medtech Co., Ltd.
+86 138-1368-7682
cyz@czmed.com
Visit us on social media:
Other

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health Watch Italy

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.